Deep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study
Neurological Sciences · 2025-12 · 46 (12) · 6923-6931
DOI: 10.1007/s10072-025-08549-1 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurological Sciences, online erschienen am 12.11.2025. Verfasst von Fabiana Giada Radicati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dept. of Neurology, Institute for Research and Medical Care IRCCS San Raffaele Pisana, Rome, Italy. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, Transcranial Magnetic Stimulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
BACKGROUND: Progressive supranuclear palsy (PSP) is a rare neuro-degenerative disease. The Deep Transcranial Magnetic Stimulation (DTMS) has been proposed as a therapeutic approach in Parkinson's Disease but there are few studies that have evaluated its efficacy in PSP. AIM AND METHODS: This was a pilot, randomized, cross-over, double blind trial, with the aim to evaluate the effect of DTMS on motor functions, freezing of gait, and cognitive performance in patients with PSP. Nineteen subjects were recruited and randomly assigned to one of the study sequences: real-sham or sham-real. Each cycle consisted of 12 sessions of high frequency DTMS over a 4-week period, separated by a 5-week wash-out period. The targets were the motor cortex and the dorsolateral prefrontal cortex. RESULTS: After adjusting for baseline scores, an interaction effect between DTMS and period of administration emerged for the PSP scale; it was estimated that the real treatment applied to the first period induced a decrease of about 0.79 points (p=0.41) and 4 point (p=0.01) when administered in the second period. Improvement in gait and be relevant since early falls and gait dysfunction have a great impact on disability. Patients and caregivers appreciated the improvements but for a short period of time (about a week). CONCLUSION: This is the first crossover, double blind, randomized clinical trial to use DTMS in patients with PSP. DMTS was associated with a motor and non-motor improvement in PSP patients. TRIAL REGISTRATION: clinicaltrial.gov: NCT02734485.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dept. of Neurology, Institute for Research and Medical Care IRCCS San Raffaele Pisana, Rome, Italy.
- San Raffaele University, Rome, Italy.
- Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
- Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele Roma, Rome, Italy.
- Dept. of Neurology, Institute for Research and Medical Care IRCCS San Raffaele Pisana, Rome, Italy. fabrizio.stocchi@sanraffaele.it.
- San Raffaele University, Rome, Italy. fabrizio.stocchi@sanraffaele.it.
Förderung
- Ministero della Salute
Zitieren
APA
Radicati, F. G., Vacca, L., Casali, M., Tremigliozzi, I., Alborghetti, M., Lombardi, M., Rossini, P. M., & Stocchi, F. (2025). Deep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study. Neurological Sciences, 46(12), 6923-6931. https://doi.org/10.1007/s10072-025-08549-1
Vancouver
Radicati FG, Vacca L, Casali M, Tremigliozzi I, Alborghetti M, Lombardi M, et al. Deep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study. Neurological Sciences. 2025;46(12):6923-6931. doi:10.1007/s10072-025-08549-1
BibTeX
@article{Radicati2025,
author = {Radicati, Fabiana Giada and Vacca, Laura and Casali, Miriam and Tremigliozzi, Ilaria and Alborghetti, Marika and Lombardi, Martina and Rossini, Paolo Maria and Stocchi, Fabrizio},
title = {Deep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study},
journal = {Neurological Sciences},
year = {2025},
volume = {46},
number = {12},
pages = {6923--6931},
doi = {10.1007/s10072-025-08549-1}
}
EUVIMED